Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLESTYRAMINE LIGHT vs AMINO ACIDS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing enterohepatic recirculation of bile acids and promoting hepatic conversion of cholesterol to bile acids, reducing serum LDL-cholesterol.
Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.
FDA: Primary hyperlipidemia (Fredrickson Type IIa) as adjunctive therapy to diet to reduce elevated serum LDL cholesterol,FDA: Relief of pruritus associated with partial biliary obstruction or primary biliary cirrhosis,Off-label: Diarrhea associated with bile acid malabsorption (e.g., post-cholecystectomy diarrhea, Crohn's disease),Off-label: Digoxin toxicity (to interrupt enterohepatic circulation, though rarely used today)
Total parenteral nutrition (TPN) for patients unable to ingest or absorb adequate nutrients,Supplementation in metabolic disorders (e.g., urea cycle disorders, maple syrup urine disease),Treatment of negative nitrogen balance due to trauma, burns, or surgery
4 g orally once or twice daily, increased gradually to 4 g 1-6 times daily; maintenance 4-24 g/day in divided doses.
1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.
Not applicable; cholestyramine is not absorbed systemically and has no plasma half-life; clinical effect duration reflects gastrointestinal transit time.
Variable; endogenous amino acids: 10–30 min for clearance from plasma; administered doses: distribution half-life ~5–10 min, terminal elimination half-life ~15–30 min, reflecting rapid metabolic utilization and renal reabsorption.
Not metabolized; acts locally in the gastrointestinal tract and is excreted unchanged in feces.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Specific pathways exist for each amino acid; excess nitrogen is converted to urea.
Primarily fecal as bile acid complex; <0.05% renal excretion of unchanged drug; negligible systemic absorption.
Renal: >95% as amino acids and metabolites, primarily reabsorbed; <5% unchanged. Fecal/biliary: negligible (<1%).
Not applicable (non-absorbed); no plasma protein binding.
Minimal for most amino acids (<10%); albumin and globulins bind tryptophan and aromatic amino acids (~80–90% for tryptophan).
Not applicable (non-absorbed); confined to gastrointestinal lumen.
0.4–0.6 L/kg (total body water); reflects equilibration with intracellular and extracellular fluid compartments.
Oral: <0.04% (minimal systemic absorption due to large molecular weight and quaternary ammonium structure).
Oral: ~90–100% (active transport across intestinal mucosa); IV: 100%.
No dosage adjustment required for renal impairment.
For GFR <30 m L/min: reduce dose to 0.5-1 g/kg/day; monitor serum amino acids and nitrogen balance.
No specific dosage adjustment recommended; caution in patients with severe hepatic impairment.
Child-Pugh B or C: avoid standard formulations; use branched-chain amino acid (BCAA)-enriched solutions at 0.8-1.2 g/kg/day.
240 mg/kg/day orally in 2-3 divided doses, not to exceed 8 g/day; adjust based on clinical response.
0.5-2 g/kg/day IV; titrate based on age, growth, and metabolic needs.
Start at low end of dosing range (4 g/day) and titrate slowly; monitor for constipation and drug interactions.
Initiate at 0.8 g/kg/day IV, adjust based on renal function and nitrogen balance; monitor for fluid overload.
No FDA boxed warning.
Patients receiving amino acid infusions should be monitored for metabolic acidosis, hyperammonemia, and renal function impairment. Solutions with electrolytes should not be used in patients with severe electrolyte imbalances.
May reduce absorption of fat-soluble vitamins (A, D, E, K), requiring supplementation,May cause hyperchloremic metabolic acidosis, especially in children with large doses,May cause constipation, which can aggravate hemorrhoids; discontinue if impaction occurs,May interfere with absorption of other drugs; administer other medications at least 1 hour before or 4-6 hours after cholestyramine,Use with caution in patients with phenylketonuria (products may contain aspartame)
Use with caution in patients with renal impairment, hepatic failure, heart failure, or metabolic acidosis. Monitor serum electrolytes, blood urea nitrogen, and ammonia levels. Avoid rapid infusion to prevent hyperosmolarity and venous thrombosis.
Complete biliary obstruction (ineffective and may cause harm),Hypersensitivity to cholestyramine or any component of the formulation
Hypersensitivity to any component, inborn errors of amino acid metabolism (e.g., phenylketonuria) without specific formula, severe hyperammonemia, anuria, or metabolic acidosis.
Cholestyramine binds to bile acids in the gut and can also bind to dietary fats and fat-soluble vitamins. Administer with food to reduce GI side effects. High-fat meals may reduce efficacy by competing for binding. Avoid concurrent intake with grapefruit juice (may alter binding). Separate ingestion from high-fat, large meals by at least 1 hour.
No significant food interactions; however, enteral nutrition should be managed to avoid excessive protein intake. Patients with phenylketonuria must avoid phenylalanine-containing amino acid solutions.
Cholestyramine is a non-absorbed resin; systemic absorption is negligible. No teratogenic effects reported in animal studies or human case reports. Risk to fetus is minimal across all trimesters.
Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimester-specific human data; animal studies show no teratogenicity at standard doses.
Breastfeeding safety: Compatible due to negligible systemic absorption. M/P ratio: Not applicable (not absorbed). No adverse effects reported in breastfed infants.
Amino acids are normal constituents of breast milk; supplementation likely results in increased maternal levels but endogenous secretion maintains relatively constant milk levels. M/P ratio not established; generally considered compatible with breastfeeding at recommended doses.
No dose adjustment required in pregnancy due to lack of systemic absorption. Ensure adequate intake of fat-soluble vitamins and consider folic acid supplementation due to potential binding.
No specific dose adjustments required for enteral amino acids. For parenteral nutrition, consider increased requirements in third trimester (protein needs up to 1.5 g/kg/day). Adjust based on maternal weight gain, renal function, and metabolic monitoring.
Cholestyramine Light contains aspartame; contraindicated in phenylketonuria. Administer other medications at least 1 hour before or 4-6 hours after cholestyramine to reduce binding. Monitor for hyperchloremic metabolic acidosis, especially in renal impairment. Constipation is common; encourage fluid intake. May reduce absorption of fat-soluble vitamins (A, D, E, K); consider supplementation.
Amino acid infusions should be administered via central line if osmolarity > 900 m Osm/L to prevent thrombophlebitis. Monitor serum ammonia and BUN in patients with hepatic or renal impairment. Use with caution in patients with inborn errors of amino acid metabolism.
Take exactly as prescribed, usually mixed with water or non-carbonated liquid; do not swallow dry powder.,Take other medications at least 1 hour before or 4-6 hours after cholestyramine to ensure proper absorption.,Drink plenty of fluids and eat fiber-rich foods to prevent constipation.,Report unusual bleeding, bruising, or dark urine (signs of vitamin K deficiency).,This product contains aspartame; avoid if you have phenylketonuria.
This medication provides essential building blocks for protein synthesis.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Inform your doctor if you have liver or kidney disease.,Do not take other protein supplements unless directed by your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLESTYRAMINE LIGHT vs AMINO ACIDS, answered by our medical review team.
CHOLESTYRAMINE LIGHT is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing enterohepatic recirculation of bile acids and promoting hepatic conversion of cholesterol to bile acids, reducing serum LDL-cholesterol.. AMINO ACIDS is a Parenteral Nutrition Solution that works by Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLESTYRAMINE LIGHT and AMINO ACIDS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLESTYRAMINE LIGHT is: 4 g orally once or twice daily, increased gradually to 4 g 1-6 times daily; maintenance 4-24 g/day in divided doses.. The standard adult dose of AMINO ACIDS is: 1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLESTYRAMINE LIGHT and AMINO ACIDS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLESTYRAMINE LIGHT is classified as Category C. Cholestyramine is a non-absorbed resin; systemic absorption is negligible. No teratogenic effects reported in animal studies or human case reports. Risk to fetus is minimal across . AMINO ACIDS is classified as Category C. Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.